PIA
TVTX icon

Piedmont Investment Advisors’s Travere Therapeutics TVTX Stock Holding History

Piedmont Investment Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-694
Closed -$19K – 2190
2018
Q2 		$19K Buy
+694
New +$18.5K ﹤0.01% 1604

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Piedmont Investment Advisors's TVTX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Travere Therapeutics (TVTX) in Q3 2018, closing a stake of 694 shares — an estimated $19K sold.

Piedmont Investment Advisors first reported a position in TVTX in Q2 2018 and held it in 1 quarter. The position peaked at $19K in Q2 2018. 128 funds tracked by Wall St. Rank hold TVTX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Travere Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 694 Travere Therapeutics shares in Q3 2018, an estimated $19K.
  • Piedmont Investment Advisors first reported a position in Travere Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Travere Therapeutics position peaked at $19K in Q2 2018.
  • 128 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.